Amicus Therapeutics (FOLD) Misses Q2 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Amicus Therapeutics Announces Second Quarter 2016 Financial Results and Corporate Updates
August 9, 2016 7:31 AM EDT
Significant Progress with EU Galafold Launch and Regulatory Submissions
Enrollment in Pompe Phase 1/2 Clinical Study on Track with Initial Data Expected in 2H16
Elevation of Time to Wound Closure as Co-Primary Endpoint in Ongoing Phase 3 Study of SD-101 for Epidermolysis Bullosa
$130 Million in Equity and Debt Proceeds Since March 31
CRANBURY, N.J., Aug. 09, 2016 (GLOBE NEWSWIRE) --... More
